BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
Key Highlights: An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of...
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in...